Compounded medications prepared by pharmacists or physicians have been used extensively throughout history as a mainstay of therapeutics. Over the past half-century – with the increasing focus on evidence based treatment the use of compounded medications substantially decreased. However, in some therapeutic areas, such as menopause, use of compounded medications continues.

The continuation of use of compounded medications represents a challenge to the USFDA because the standard evaluations of benefit and risk are not required.
To gain guidance in this concern the FDA asked the National Academies of Sciences, Engineering and Medicine to form a consensus committee to characterize the clinical utility of compounded bioidentical hormone therapy.
The committee was chaired by Dr. Donald Mattison the Chief Medical Officer of Risk Sciences International and composed of a dozen clinicians and scientists who worked together over the course of 1.5 years to pull the literature on risk-benefit, and clinical utility of compounded bioidentical hormone therapy. The publication can be downloaded here.
The committee concluded (Conclusion 9.1) that there is insufficient evidence to support the overall clinical utility of compounded bioidentical hormone therapy as treatment for menopause and male hypogonadism symptoms.
More RSI News
RSI and Engineers Canada are partnering to offer an online version of the introductory workshop on the PIEVC Protocol for infrastructure climate risk and vulnerability…
Read News ItemWritten by experts in the field, Blood Safety: A Guide to Monitoring and Responding to Potential New Threats offers a concise yet comprehensive overview on critical issues in monitoring…
Read News ItemEngineers Canada is a partner with the German development agency Deutsche Gesellschaft für Internationale Zusammenarbeit GmbH (GIZ) in the execution of their Enhanced Climate Services…
Read News ItemThe OPTrust Climate Change Symposium being held NOVEMBER 19-20, 2018 in TORONTO offers an opportunity to provide new insights into how to face climate change…
Read News Item